Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a novel RNA virus from the betacoronavirus family. Members of the coronavirus family have adapted to human hosts and effectively get ...
Background: There is growing evidence that cardiovascular diseases are relatively more prevalent in subjects who feel anxious. An increased clotting diathesis might subject anxious individuals to an ...
NEWARK, Del, Feb. 13, 2023 (GLOBE NEWSWIRE) -- The global hypercoagulability treatment market is predicted to generate a market value of US$ 670 million in 2023 and a market value of US$ 1,317.99 ...
Context: In vitro studies and anecdotal clinical reports have suggested that clinically significant rebound hypercoagulability may occur after discontinuation of oral anticoagulants (OACs), such as ...
The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2), is characterized by a range of clinical presentations. The vascular ...
Incidence of thrombotic complications in patients with COVID-19 who are critically ill is high, with an estimated incidence of 31% for arterial or venous thromboembolism (VTE), acute pulmonary ...
TYPE 2 diabetes means the body doesn't use insulin properly - a hormone which regulates a person's blood sugar levels. Without proper treatment, toxic amounts of sugar can build up in the bloodstream, ...
The global hypercoagulability treatment market is expected to garner a market value of US$ 670 million in 2023 and is expected to accumulate a market value of US$ 1,317.99 million by registering a ...
Credit: Getty Images More than 20% of ischemic strokes in patients aged 45 years or younger are associated with Antiphospholipid syndrome, but its exact etiology and pathophysiology are not yet fully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback